Cleveland BioLabs is a clinical-stage biotechnology company focused on leveraging deep mechanistic understanding of apoptosis – the cell death process – to develop a strong pipeline of compounds chiefly focused on oncology applications and mitigation of radiation injury. The company’s lead compound is currently being developed as both a radiation countermeasure and a cancer treatment. Cleveland BioLabs has two operating subsidiaries: Incuron LLC and Panacela Labs, Inc., as well as strategic relationships with various entities. For more information, visit the company’s Web site at www.cbiolabs.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: